3 ms·
I can buy the argument that just shoveling huge amounts of aid to people doesn't fix anything long-term. But it's not solely a decision between that and no char
by _delirium 16y ago
I can buy the argument that just shoveling huge amounts of aid to people doesn't fix anything long-term. But it's not solely a decision between that and no charity. He mentions employment, which often benefits from having a stock of not-yet-exploited research to commercialize (SV firms do a lot of innovation, but they also do a lot of commercialization of stuff for which the early-stage R&D was done in academia, at government research labs, etc.).
Charities funding research, and especially insisting that the research be published in some open-access and not-patent-encumbered form, can provide that raw material that new companies need. Charity-funded medical research can also directly produce treatments that improve conditions in a region long-term. And, although it runs into a bunch of political controversy, same for charity-funded research on things like new crop varieties.
- byrneseyeview 16y agothey also do a lot of commercialization of stuff for which the early-stage R&D was done in academia, at government research labs, etc. So they turn it from something of theoretical value to something that actually improves people's lives--to the point that they're willing to part with money to have it? That seems to add a lot more utility on the margin. Of course, it wouldn't mean anything if there weren't inventions to subsidize.
- _delirium 16y agoYeah, I'm not arguing that commercialization isn't useful; it's the main way theoretically valuable ideas get actually produced. But I think it can be very helpful to innovative industries to have this big stock of theoretically-valuable ideas waiting to be mined for commercialization. Otherwise you either only get incremental advances, or you need big firms with their own R&D groups (like Microsoft Research). You can also have startups based on blue-skies research in some areas (especially pharma), but investors in most areas are pretty wary of funding a startup that has too much basic research in their critical path, due to the high risk.